An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris

Trial Profile

An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs CB 03 01 (Primary) ; CB 03 01 (Primary)
  • Indications Acne vulgaris
  • Focus Pharmacodynamics
  • Sponsors Cassiopea
  • Most Recent Events

    • 15 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2017.
    • 15 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.
    • 15 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top